Non-Small Cell Lung Cancer
Conditions
Interventions
Observation group of non-small cell lung cancer:None
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients aged 18 years or above, diagnosed with stage IV (according to the 8th edition of AJCC) or stage III NSCLC that is not surgically resectable through histological or cytological examination. 2. Confirmed to have EGFR sensitive mutations (including but not limited to 19del or L858R) through laboratory tests. 3. Currently receiving or planning to receive third-generation EGFR-TKIs (such as osimertinib, aminorestatinib, volunetinib, etc.) and planning to combine with radiotherapy. 4. Have signed the informed consent form (signed by the individual or their legal guardian) and are willing to follow the study follow-up plan.
Exclusion criteria
Exclusion criteria: 1. There are clear contraindications for three generations of EGFR-TKI or radiotherapy (such as: allergy to the active ingredients or excipients of targeted drugs; history of interstitial pneumonia; inability to tolerate the planned dose of important organs within the radiotherapy field, etc.). 2. According to the investigator's assessment, patients who are scheduled to switch to other systemic treatments, including chemotherapy, immunotherapy, or anti-angiogenic therapy, etc. 3. The expected survival period is less than 3 months, or the ECOG score is >= 3 points. 4. Within the past 5 years, there has been a history of other malignant tumors, but they have been completely relieved and do not require further treatment (such as cervical carcinoma in situ, papillary thyroid carcinoma, etc.). 5. According to the investigator's judgment, there are any circumstances that would make it inappropriate for the patient to participate in this study in their best interest (such as harming the patient's health) or may hinder, limit or interfere with the evaluation as stipulated in the research protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient-Reported Outcome Assessment;Patient and Disease Characteristics Assessment;Treatment Pattern Assessment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy Assessment;Safety Assessment;Disease Progression Assessment; | — |
Countries
China
Contacts
Public ContactYongmei Liu
West China Hospital of Sichuan University
Outcome results
None listed